$ALKSAlkermes plc.

📅 Upcoming

🕒 Recent(90d)

News

• An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
  Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
  biopharma_dive · 12d ago
• STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
  Novo Nodisk outlined plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines
  stat · 13d ago
• STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
  The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
  stat · 14d ago
• With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
  Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of…
  fiercebiotech · 16d ago
• ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
  As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.
  fiercebiotech · 1mo ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 2mo ago